Improvements in the sensitivity and specificity of laboratory testing methods for Chlamydia trachomatis infections in recent years have created potential problems with interpreting data on chlamydia prevalence trends. A switch to a more sensitive test can result in an increase in chlamydia positivity even with no increase in the true disease prevalence. To examine the impact of switching laboratory testing methods on chlamydia positivity trends among women, the authors analyzed data from chlamydia screening programs in family planning clinics in two geographic areas of the United States. Data from 7,287 tests performed in Philadelphia, Pennsylvania, indicated a 46% increase in positivity (from 4.1% to 6.0%) when the clinics switched from a nucleic acid probe assay to a ligase chain reaction test. Data from 35,306 tests performed in Oregon and Washington State laboratories showed a 21% increase in positivity (from 3.3% to 4.0%) when clinics switched from a direct immunofluorescent antibody testing procedure to an enzyme immunoassay with negative gray zone confirmation. These increases were within ranges consistent with the variability of the testing methods and occurred primarily in asymptomatic women and in women over age 20 years. Any switch in laboratory testing methods must be considered when interpreting data on chlamydial infection trends. Am J Ep/ctem/o/2000;151: 430-5. chlamydia; Chlamydia trachomatis; laboratory techniques and procedures; mass screening; prevalence Laboratory testing methods for Chlamydia trachomatis infections have evolved rapidly since the early 1980s, when the standard approach consisted of the isolation of the organism in cell culture (1). Antigen and nucleic acid detection technologies were developed and have become widely used in chlamydia screening and treatment programs in the 1990s. Although these tests are generally no more and sometimes less sensitive than culture, they are used because they cost less, require less expertise to perform, specimens are easier to transport, and the tests provide results more quickly than culture.
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With continuing advances in technology, new chlamydial tests have become available and offer improvements in sensitivity and specificity. Some chlamydia screening programs have switched to these new tests, creating potential problems for interpreting trends in the prevalence of C. trachomatis infections in those areas. Specifically, a switch to a more sensitive test could result in an increase in chlamydia test positivity in the absence of any change in disease prevalence, leading to a misinterpretation of reported disease trends. Previous studies have suggested that the increase in the sensitivity of chlamydial tests may be relatively greater for asymptomatic women than for women with symptoms or clinical indicators of inflammation (e.g., mucopurulent cervicitis) (2) (3) (4) . Compared with women with symptoms, asymptomatic women are more likely to have small numbers of chlamydial organisms present in collected samples (4) . Thus, an increase in chlamydia test positivity after a switch to a more sensitive test might be more apparent among asymptomatic women. The purpose of this analysis was to evaluate under field conditions the effect of switching laboratory tests on chlamydia positivity trends among women and how these effects may vary based on patient characteristics.
MATERIALS AND METHODS
The authors analyzed the results of tests for C. trachomatis infections performed on specimens collected from women as part of Regional Infertility Prevention Programs in two federal Public Health Service Regions (5) . In November 1996, in Region m, the Philadelphia, Pennsylvania, family planning clinics switched from a laboratory using a nucleic acid probe (DNA probe) assay (Pace 2®, Gen-Probe, San Diego, California) to a laboratory using a ligase chain reaction (LCR) test (LCx® LCR, Abbott Laboratories, North Chicago, Illinois). Data were analyzed from tests performed on 7,287 cervical specimens for the Philadelphia family planning clinics from January 1996 through March 1997. In January 1994, in Region X, the state public health laboratories in Oregon and Washington State switched from a standardized direct immunofluorescent antibody (DFA) testing procedure (MicroTrak® DFA, SyvaBehring, Palo Alto, California) to an enzyme immunoassay (EIA) with negative gray zone confirmation (MicroTrak® EIA, MicroTrak® DFA, Syva-Behring). This testing procedure, which has been shown to increase test sensitivity, involved using a DFA method to retest specimens for which results were in the EIA negative gray zone (i.e., the narrow range just below the positive cut-off which contains a significant number of false negatives relative to the number of true negatives). If the confirmatory DFA test was positive, the test was reported as positive (1) . Data were analyzed from tests performed on 35,306 cervical specimens in the Oregon and Washington State laboratories for Region X family planning clinics from January 1993 through June 1994.
The data collected for each specimen included the type of chlamydial test performed, date of specimen collection, test result, and demographic data for the woman tested. Information on clinical findings and behavioral risk history were collected for all women tested in Region X.
Chlamydia positivity was defined as the number of positive test results divided by the total number of tests that were positive or negative; this was used as a surrogate for prevalence (6) . Positivity was calculated for 3-month periods before and after the switch in tests occurred. The observed percent change was calculated using the positivity for the laboratory test used prior to the switch and the positivity for the laboratory test used after the switch.
We examined the observed percent change in positivity in each region by a variety of factors, depending on the availability of regional data. We evaluated the observed percent change in positivity by age of the woman tested (<20 years, 20-24 years, >25 years) for both regions. We used Region X data to examine the observed percent change in positivity by laboratory (Oregon versus Washington State), the presence of any clinical findings in the woman tested (mucopurulent cervicitis (MPC), friable cervix, or pelvic inflammatory disease (PID)), and by whether the woman reported that her sex partner was symptomatic, which could indicate possible recent exposure to chlamydia.
We calculated an expected percent change in positivity associated with the switch in testing procedures in the absence of any change in disease prevalence. Specifically, we used the observed positivity in the 3 months before the test switch along with that test's sensitivity and specificity to calculate an adjusted chlamydia positivity (7). This adjusted positivity was an estimate of the true chlamydia prevalence. Using this adjusted positivity and the sensitivity and specificity of the test used after the switch, we calculated the percent of tests that we would expect to be positive using the new test (i.e., the expected positivity after the test switch). The expected percent change in positivity was calculated using this expected positivity after the test switch and the observed positivity before the switch. We used 95 percent confidence intervals for the sensitivity and specificity of the chlamydial tests to construct ranges for the adjusted positivity, the expected positivity, and the expected percent change in positivity after the switch in laboratory tests. The laboratory test sensitivities and specificities and 95 percent confidence intervals used in these calculations were based on chlamydial test evaluations done under field conditions within Region III and Region X (8, 9) (table 1). 
RESULTS
In Region III, the observed chlamydia positivity based on the nucleic acid probe assay was 4.1 percent in the last quarter of 1996 preceding the switch in laboratory test (figure 1). After the switch to LCR in the first quarter of 1997, the observed positivity increased to 6.0 percent, a 46 percent increase. In Region X, the observed chlamydia positivity based on the DFA test method was 3.3 percent in each of the two quarters in 1993 preceding the switch in laboratory test (figure 2). When the laboratories switched from the DFA method to the EIA test with negative gray zone confirmation in the first quarter of 1994, the chlamydia positivity increased to 4.0 percent, a 21 percent increase.
The observed increases in positivity after the change in laboratory tests were within the expected ranges. In Region III, an increase in positivity of 43 percent (range 26 percent to 68 percent) was expected when switching from the DNA probe to the LCR test (table  2) . A 46 percent increase was observed in the data. In Region X, an increase in positivity of 14 percent (range 5-26 percent) was expected when switching from the DFA to the EIA test with negative gray zone confirmation. The data showed an actual increase of 21 percent.
In both Region III and Region X, the increase in positivity after the switch in laboratory testing methods was smallest among women less than 20 years of age (table 3) . In Region X, similar increases in positivity were observed after the change from DFA to EIA with negative gray zone confirmation in both the Oregon and Washington State laboratories. Among women with no clinical findings, a 24 percent increase in chlamydia positivity was observed. However, no increase in positivity was found for women who presented with MPC, PID, or a friable cervix at the time of their examination. Similarly, no increase in positivity was found for women who reported having a symptomatic sex partner, compared with a 22 percent increase in chlamydia positivity for women who did not report such an exposure.
DISCUSSION
Increases in chlamydia positivity were observed when laboratories in two geographic areas of the United States switched to more sensitive methods for the detection of C. trachomatis infection. The increases occurred primarily in women aged 20 years and over, and in women with no reported clinical findings or whose partners were not reported to be symptomatic at the time of the test.
The observed percent changes in both geographic regions were within expected ranges consistent with the variability in the sensitivity and specificity of the t Adjusted positivity = (observed positivity before switch + specificity of test used before switch -^/(sensitivity of test used before switch + specificity of test used before switch -1).
$ Expected positivity = [(adjusted positivity) x (sensitivity of test used after switch + specificity of test used after switch -1)] -(specificity of test used after switch -1).
§ Expected % change = [(expected positivity after switch -observed positivity before switch)/(observed positivity before switch)] x 100. 1) Observed % change = [(observed positivity after switch -observed positivity before switch)/(observed positivity before switch)] x 100. laboratory tests used. However, the difference in the point estimates between observed and expected values in Region X was substantial. It is unlikely that this difference was due to an increase in the true chlamydia positivity since the chlamydia positivity during the 6 months before the switch was relatively stable. On the other hand, it is possible that the performance of the tests varied in these particular laboratories during the months for which the data were analyzed, or that variations in specimen collection procedures affected the test performance.
The smaller observed increases in chlamydia positivity among younger women as well as the lack of an increase in chlamydia positivity among women with clinical findings or possible recent exposure to chlamydia indicated that the previously used testing methods may be very sensitive among these subgroups of women. The newer testing methods appeared to detect more infections in older and asymptomatic women. These findings are consistent with previous studies that showed that the performance of some chlamydial tests can be affected by individual patient characteristics (2-4). In particular, younger women and women with concurrent sexually transmitted infections have been found to have higher chlamydial inclusion counts, which could make infection easier to detect, regardless of testing method (10) . Women with no clinical findings at the time of their examination accounted for more than 90 percent of the tests performed by the Region X laboratories during the study period. Thus, the switch to the more sensitive testing method had a large impact on the overall chlamydia positivity.
A number of factors can affect the interpretation of chlamydia positivity trend data, including the stability of the population being tested over time, variability in test performance resulting from the use of multiple laboratories, and the criteria used to determine which women to test. In • this analysis, the population of women being tested for chlamydia in the family planning clinics was stable over the short time period of the study, and the test criteria were consistent in each geographic area during the study period. Although there could have been variability in test performance in the limited number of laboratories in this analysis, separate analyses by laboratory produced consistent findings.
Changing laboratory tests for chlamydial infection can affect the interpretation of trends in chlamydia positivity. Specifically, when laboratories in an area switch to a more sensitive test, the chlamydia positivity in that area may appear to increase even when there is no increase in the underlying true chlamydia prevalence. Characteristics of the women being tested could affect the magnitude of the increase. It has been estimated that 98 percent of chlamydia tests performed in the United States in 1994-1995 were non-culture tests, primarily DNA probe (49 percent) and EIA tests (29 percent) (11) . As more laboratories switch to newer, more sensitive testing methods, i.e., DNA amplification tests, it will be important to track when and where the new testing methods are being used and consider this information when interpreting data on C. trachomatis infection trends. This methodological approach could also be applicable to studying the epidemiology of other diseases, including other sexually transmitted diseases, where improvements in testing technology can lead to increased detection.
